 |
New Therapeutic Approaches to Treat Medullary Thyroid Carcinoma CME DisclosuresRelease Date: December 10, 2007; Valid for credit through December 10, 2008 |
| Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | |
| Contents of This CME Activity | |
| Medullary thyroid carcinoma arises from parafollicular calcitonin-producing C cells and accounts for 5% to 8% of all thyroid cancers, and may be sporadic or hereditary. Although most cases respond to curative surgery, disease can persist, recur, or metastasize, and new treatments are available to improve prognosis. - New Therapeutic Approaches to Treat Medullary Thyroid Carcinoma
Martin Schlumberger, MD
Francesca Carlomagno, MD
Eric Baudin, MD
Jean Michel Bidart, PhD
Massimo Santoro, MD
Go to Test Questions |
| Legal Disclaimer | |
| The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2007 Medscape. |
|
|
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
